SUMMARY
Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne viral disease with high mortality rates and significant public health implications. Despite its global prevalence, the mechanisms underlying its pathogenesis remain poorly understood, and effective diagnostic and therapeutic tools are limited. Metabolomics, as a powerful tool for exploring host-pathogen interactions, offers a promising avenue for identifying biomarkers and elucidating disease mechanisms. In this study, we investigated the metabolic alterations in CCHF patients using non-targeted metabolomics to enhance understanding of disease pathogenesis, improve diagnostic capabilities, and identify potential therapeutic targets. A nationwide analysis was conducted on the blood serum of 29 CCHF patients and 10 healthy controls, employing Nuclear Magnetic Resonance (NMR) spectroscopy. Serum samples were collected over four consecutive days, and metabolic profiling was performed using Partial Least Squares Discriminant Analysis (PLS-DA) and Variable Importance in Projection (VIP) scoring to identify key metabolic pathways and compounds. Significant disruptions in metabolic pathways were observed in CCHF patients, particularly in purine and pyrimidine metabolism, the TCA cycle, and redox-related processes. Elevated levels of metabolites such as S-adenosyl homocysteine (SAH), guanosine triphosphate (GTP), inosine monophosphate (IMP), adenosine monophosphate (AMP), carnosine, 2’-deoxyuridine, nicotinamide adenine dinucleotide phosphate (NADP+), and maleate were identified. These metabolites demonstrated potential as biomarkers for disease severity and progression, with distinct metabolic profiles observed between moderate and severe cases. This study provides the first comprehensive metabolomic analysis of CCHF, highlighting critical metabolic pathways disrupted during infection. The findings underscore the utility of NMR-based metabolomics for identifying biomarkers that facilitate early diagnosis, prognosis, and therapeutic development. These results pave the way for future research to validate the identified biomarkers and explore targeted treatment strategies to improve patient outcomes in this severe viral infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CD acknowledges support from TUBITAK (Project No: 221S353). The authors acknowledge the use of the services and facilities of n2STAR-Koc University Nanofabrication and Nanocharacterization Center for Scientific and Technological Advanced Research. The authors gratefully acknowledge use of the services and facilities of the Koch University Is Bank Infectious Disease Center (KUIS-CID).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Koç University Ethics Committee and all the procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee ethical standards. A written informed consent was obtained from all patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Improved main text and title
Data Availability
All data produced in the present study are available upon reasonable request to the authors
